« Back to Directory of Resources
Treatments Under Development
Here you will find a list of current treatments under development:
| Brand Name: | Kyprolis |
| Generic Name: | carfilzomib |
| Useful Links: | News articles, forum discussions |
| Code Name: | PR-171 |
| Company: | Onyx Pharmaceuticals |
| FDA Clinical Phase: | 1, 2, & 3 |
…
| Brand Name: | Doxil | |
| Generic Name: | doxorubicin HCl liposome injection | |
| Code Name: | ||
| Company: | Ortho Biotech | |
| FDA Clinical Phase: | 1,2, & 3 |
Description:
Doxil is a form of the anticancer drug doxorubicin that is contained in very tiny, fat-like particles.| Brand Name: | Aplidin |
| Generic Name: | plitidepsin |
| Code Name: | |
| Company: | PharmaMar, SA |
| FDA Clinical Phase: | 3 |
Description:
Aplidin is derived from a compound found in tunicates which shows promise in shrinking tumors.| Brand Name: | |
| Generic Name: | dacetuzumab |
| Code Name: | SGN-40 |
| Company: | Seattle Genetics Inc. |
| FDA Clinical Phase: | 1 |
Description
Dacetuzumab is a monoclonal antibody that specifically binds to and works against a molecule called a CD40 receptor, which appears in abnormally high amounts in …
| Brand Name: | |
| Generic Name: | |
| Code Name: | SNS01-T |
| Company: | Senesco |
| FDA Clinical Phase: | 1/2 |
Description:
SNS01-T is a small inhibitory RNA molecule that blocks the expression of Factor 5A mRNA. The Factor 5A gene has been shown to regulate the expression of …
| Brand Name: | |
| Generic Name: | |
| Code Name: | MAGE-A3 and NY-ESO-1 |
| Company: | University of Arkansas |
| FDA Clinical Phase: | 2/3 |
Description:
The purpose of MAGE-A3 and NY-ESO-1 immunotherapy is to generate anti-myeloma T-cells (natural immune system cells) to kill myeloma cells and nothing else.